Chicago, March 13, 2019 - Veradigm®, an Allscripts (NASDAQ: MDRX), business unit, announced today that it has strengthened its strategic relationship with Pulse8, a leader in healthcare analytics and technology company.
Pulse8 is the first, and only with a patent pending, healthcare analytics and technology company delivering a complete enterprise platform to provide visibility into the efficacy of Risk Adjustment, Quality Improvement, and Pharmacy Management programs. Pulse8 enables both health plans and at-risk providers to achieve precise risk and quality scores in the Medicare Advantage, Managed Medicaid, and ACA Commercial markets as well as with Value-Based Payment models for Medicare. Pulse8’s Illumin8™ Active Intelligence™ platform offers a suite of uniquely pragmatic solutions that are powered by patent-pending Dynamic Intervention Planning to deliver cost-effective and appropriate interventions for closing gaps in documentation, coding, and quality.
Pulse8 strengthens Veradigm’s existing health plan product suite that delivers tools and services to help control costs while optimizing health outcomes for health plan members. The newly combined offering of clinical data exchange solutions, cutting-edge analytics, and point-of-care engagement tools supports Veradigm’s commitment to health plans and health care providers in their drive towards quality outcomes while maximizing return on investment.
“The type of analytics, technology capabilities, and market knowledge that Pulse8 brings to our team complements and strengthens Veradigm’s existing health plan portfolio. John Criswell, CEO, Pulse8, will be responsible for leading our combined efforts,” said Tom Langan, CEO of Veradigm. “The move reflects our strategy to extend and enhance existing solutions in bold new ways to improve healthcare quality, risk score accuracy, and healthcare cost reduction.”
“Pulse8 is dedicated to re-imagining data to help people live healthy and independent lives through the innovation of sophisticated analytics, predictive techniques, and data collection tools that eliminate waste in healthcare,” John Criswell, CEO, Pulse8. “We look forward to working together to achieve success and return on investment for our health plan and provider partners. Collectively, we now have the capability to expand our mission to deploy solutions that improve financial performance and generate significant ROI for payers and at-risk providers.”
Pulse8 will be hosting a Pre-Conference Workshop that pairs Pulse8’s industry experts with some notable health plan partners on Sunday, March 17th as a platinum sponsor at the 2019 RISE Nashville Summit. The annual RISE Nashville Summit continues to be the most meaningful conference for professionals of all levels in the Medicare Advantage, Medicaid, and ACA Market.
Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media. Our solutions are designed to help key healthcare stakeholders to improve the quality, efficiency, and value of healthcare delivery - from biopharma to health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. That is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com, Twitter, Facebook and LinkedIn.
Veradigm® is a division of Allscripts.
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2019 Veradigm™ Allscripts Healthcare LLC and/or its affiliates All rights reserved. Cited marks are the property of Allscripts Healthcare, LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com
Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com